FDAzilla

/FDAzilla

Govzilla and FOI Services Announce Strategic Partnership

Govzilla and FOI Services announced Tuesday, April 16th, 2019 the beginning of their official partnership that integrates FOI Services’ unique and vast dataset with Govzilla’s innovative analytics tools to help solve regulatory intelligence problems. FDA regulated industries' need for immediate access to enforcement documents is growing as more companies expand their markets and supply chains across the globe. The ability [...]

By |2019-04-18T15:44:43-05:00April 18th, 2019|FDAzilla|

Week of March 31st, 2019 | FDA Sent These Warning Letters to Pharma/Device Companies

Enforcement in terms of warning letter posting was busy this week. Among those issued were four that were sent to homeopathic drug product manufacturers, continuing a focus evident over the past two years. In addition, there were another two to drug product manufacturers and one to an in vitro diagnostics firm.

Week of March 10th, 2019 | FDA Sent These Warning Letters to Pharma/Device Companies

Warning letters posted this week include ones demonstrating FDA’s continued focus on over-the-counter (OTC) product manufacturers and manufacturers in India, including a particularly testy letter to Pfizer for a Hospira site in India that they are closing.